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The immuno-regulatory mechanisms of IL-10-producing type 1 regulatory T (Tr1) cells have
been widely studied over the years. However, several recent discoveries have shed new
light on the cellular and molecular mechanisms that humanTr1 cells use to control immune
responses and induce tolerance. In this review we outline the well known and newly dis-
covered regulatory properties of human Tr1 cells and provide an in-depth comparison of
the known suppressor mechanisms of Tr1 cells with FOXP3+ Treg. We also highlight the
role thatTr1 cells play in promoting and maintaining tolerance in autoimmunity, allergy, and
transplantation.
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INTRODUCTION
The original study that led to the discovery of interleukin (IL)-
10-producing type 1 regulatory T (Tr1) cells began in the late
eighties when the immune system of a severe combined immun-
odeﬁciency (SCID) patient, who developed long-term mixed
chimerism after HLA-mismatched fetal liver hematopoietic stem
cell transplant (HSCT), was analyzed to understand how toler-
ance was acquired. This patient did not develop graft-versus-host
disease (GvHD) in the absence of immunosuppressive therapy,
despite having host-speciﬁc CD4+ T helper and CD8+ cytolytic
T cells of donor origin, suggesting that an allo-regulatory sup-
pressor mechanism(s) was responsible for maintaining tolerance
(Roncarolo et al., 1988). Interestingly, allo-reactive CD4+ T cell
clones isolated from this transplanted patient had a cytokine pro-
ﬁle distinct from both type 1 and type 2 helper T cells (Th1 and
Th2, respectively), since they produced IL-5, IFN-γ, and GM-CSF,
low levels of IL-2, but not IL-4 (Bacchetta et al., 2002), suggest-
ing that these T cell clones were a unique population of T cells.
Pursuant to the cloning of human IL-10 (Vieira et al., 1991), a
second tolerant SCID patient who underwent HLA-mismatched
HSCT was found to have high plasma levels of IL-10, and a signif-
icant proportion of donor-derived CD4+ T cell clones speciﬁc
for the host HLA antigen (Ag)s that produced IL-10 at high
levels (Bacchetta et al., 1994). A few years later, Groux et al.
(1997) demonstrated in mice and humans that IL-10-producing
CD4+ T cells, are indeed, a distinct subset of T cells that are
Ag-speciﬁc and immunosuppressive and can mediate immune-
tolerance. Together, these ﬁndings led to a new classiﬁcation of
IL-10-producing CD4+ T cells appropriately named Tr1 cells.
Since their seminal discovery, a ﬁnding that predates the identiﬁ-
cation of the more widely studied CD4+CD25+ regulatory T cells
(Treg) (Sakaguchi et al., 1995), Tr1 cells have proven to be impor-
tant in mediating tolerance in several T cell mediated diseases
(review in Roncarolo et al., 2006, 2011; Roncarolo and Battaglia,
2007).
Apart from being detected in SCID patients after allogeneic
HSCT (Bacchetta et al., 1994), Tr1 cells have been described in β-
thalassemic patients who developed persistent mixed chimerism
(Seraﬁni et al., 2009). These tolerant β-thalassemic patients had
high levels of IL-10 in peripheral blood and an increased per-
centage of IL-10-producing CD4+ T cells compared to nor-
mal donors. Moreover, allo-speciﬁc Tr1 cell clones isolated from
patients’ peripheral blood suppressed alloAg-speciﬁc T cell prolif-
eration and cytokine production in an IL-10 dependent manner
(Seraﬁni et al., 2009). Overall, the results from tolerant HSCT
patients indicate that Tr1 cells are associated with long-term
chimerism, possibly induced through chronic exposure to alloAgs
after transplantation.
Interleukin-10-producing Tr1 cells have also been demon-
strated in an array of different immune-mediated diseases. For
example, Tr1 cells speciﬁc for self-Ags such as desmoglein 3 and
islet Ags have been described in pemphigus patients (Veldman
et al., 2004) and diabetes patients (Tree et al., 2010), respectively.
Furthermore, Tr1 cells speciﬁc for the foreign-Ags gliadin in celiac
disease (Gianfrani et al., 2006), and for nickel (Cavani et al., 2000),
Derp 1 (Akdis et al., 2004), and bee-venom (Meiler et al., 2008)
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in allergic patients have been reported. Conversely, the absence of
Tr1 cells in acute viral infections correlates with clearance of the
virus, while the presence of Tr1 cells is associated with viral per-
sistence in chronic viral infections such as HIV, HCV, and HBV
(Granelli-Piperno et al., 2004; Ha et al., 2008), and in bacterial
infections such as Bordetella pertussis (McGuirk et al., 2002) and
Mycobacterium tuberculosis (Boussiotis et al., 2000; McGuirk et al.,
2002).
In this review we provide an overview of the similarities
and differences between human Tr1 cells and forkhead box P3
(FOXP3)-expressing CD4+CD25+ Treg cells (FOXP3+ Treg) by
summarizing their cellular andmolecular suppressivemechanisms
and describe the current knowledge of their safety and efﬁcacy in
clinical trials.
Treg SUBSETS: DIFFERENT CELLS SHARING SIMILAR
MARKERS
Regulatory T cells are a fundamental component of a healthy
immune system since they play a vital role in ﬁne-tuning the
balance between effector and tolerogenic immune responses. It
is well documented that a deﬁciency in Treg frequency or num-
ber, or a defect in their function can lead to inﬂammation and/or
autoimmune diseases (Roncarolo and Levings, 2000; Roncarolo
and Battaglia, 2007; Sakaguchi et al., 2008). Over the years, several
types of Treg populations have been identiﬁed: TGF-β secreting,
Type 3 helper cells (Th3; Miller et al., 1992), CD8+CD28− T cells
(Liu et al., 1998), HLA-E-speciﬁc CD8+ T cells (Jiang et al., 2010),
etc. but, to date, the best characterized are the FOXP3+ Treg (Hori
et al., 2003;Khattri et al., 2003) and theCD4+ IL-10-producingTr1
cells (Groux et al., 1997; Barrat et al., 2002;Akdis et al., 2004). Their
distinct intracellular and surface markers and cytokine expression
proﬁle distinguish FOXP3+ Treg and Tr1 cells from one another.
FOXP3+ Treg are identiﬁed by standard ﬂow cytometry techniques
basedon their constitutively high expressionof CD25 and the tran-
scription factor FOXP3 (Sakaguchi, 2005). FOXP3+ Treg can be
subcategorized into naturally occurring FOXP3+ Treg (Yagi et al.,
2004), which are selected in the thymus, and adaptive FOXP3+
Treg (Fantini et al., 2004; Tran et al., 2007; Horwitz et al., 2008;
Lu et al., 2010) that are induced in the periphery, based on the
surface expression of Helios, which is found only on the for-
mer population (Thornton et al., 2010). In addition, the naturally
occurring FOXP3+ Treg are identiﬁed and distinguished from acti-
vated CD4+ T cells by the expression of low levels of CD127 (Liu
et al., 2006; Seddiki et al., 2006), and of CD49d (Kleinewietfeld
et al., 2009), and by the DNA demethylation of a speciﬁc region of
the FOXP3 gene called Treg-speciﬁc demethylated region (TSDR;
Baron et al., 2007). Furthermore, the expression of CD45RA dis-
tinguishes naïve from activated FOXP3+ Treg and from activated
conventional CD4+ T cells (Hoffmann et al., 2006; Miyara et al.,
2009).
Type 1 regulatory T cells, on the other hand, are a more dis-
crete population of Treg that are induced in the periphery which,
to date, lack a deﬁne cell surface signature. Similar to other human
effector T cells (Allan et al., 2007; Passerini et al., 2008), Tr1 cells
transiently express FOXP3 upon activation (Levings et al., 2005,
and S. Gregori and M. G. Roncarolo, personal communication);
however, FOXP3 expression in Tr1 cells is not maintained after
activation and never reaches the high expression levels charac-
teristic of FOXP3+ Treg. Furthermore, FOXP3 is not required
for Tr1 cell induction or function since suppressive Tr1 cells
can be generated or isolated from peripheral blood of patients
with immunedysregulation polyendocrinopathy enteropathy X-
linked (IPEX), a disease condition due to FOXP3-mutations, even
in those patients with complete deletion of FOXP3 (Passerini
et al., 2011). The rapid onset of autoimmune-mediated wast-
ing disease after birth in IPEX patients indicates that, although
Tr1 cells can be induced they are not present or sufﬁcient to
control aggressive autoimmunity early in life. The naturally occur-
ring FOXP3+ Treg, which are present from birth, are immedi-
ately effective especially to modulate self-reactivity, whereas Tr1
cells are induced in the periphery and are involved in regula-
tion later on in life. Therefore, Tr1 cells and naturally occurring
FOXP3+ Treg in humans are distinct subsets of cells with reg-
ulatory activity that co-operate in promoting and controlling
tolerance in vivo.
Type 1 regulatory T cells are currently identiﬁed by their unique
cytokine proﬁle consisting of high levels of IL-10, TGF-β, low lev-
els of IL-2, variable levels of IL-5 and IFN-γ, in the absence of IL-4
after stimulation (Groux et al., 1997). The reliance on a cytokine
proﬁle to distinguishTr1 cells fromotherT cell subsets complicates
their identiﬁcation and study since Tr1 cells are not the only T cell
subset that secretes IL-10. Other T cell subsets such as FOXP3+
Treg (Ito et al., 2008), Th1 and Th2 cells (Yssel et al., 1992; Del
Prete et al., 1993; Chang et al., 2007; Saraiva et al., 2009), Th9
(Veldhoen et al., 2008), and Th17 (McGeachy et al., 2007) can
also express IL-10, depending on stimulation and environmen-
tal conditions. For example, the strong stimulation of Th1 cells
via T cell receptor (TCR) in the presence of high levels of IL-
12p70 can result in the induction of IL-10 production (Gerosa
et al., 1996); however it is unclear if the induced IL-10 expres-
sion remains ﬁxed once the environmental stimuli is removed.
Tr1 cell clones display a distinct kinetics of IL-10 secretion, since
IL-10 is detectable in culture supernatants at high concentrations
early after Ag-speciﬁc activation and is maintained over the life
of the cell (Bacchetta et al., 1994), whereas IL-10 production by
either Th cell clones or peripheral blood cells occurs late after
stimulation and never reaches the level of Tr1 cells (Yssel et al.,
1992; de Waal Malefyt et al., 1993). The reason why Tr1 cells
are able to secrete high levels of IL-10 shortly after activation is
unknown; however, it is possible that the high levels of IL-10 secre-
tion is a result of chromatin remodeling at the IL-10 locus, which
allows Tr1 cells to readily secrete IL-10 upon activation and to
bypass IL-10 repression (Trinchieri, 2007). Answering this ques-
tion will help to determine if Tr1 cells are a truly ﬁxed lineage of
cells or if Tr1 cells are plastic like the other T cell subsets such as
FOXP3+ Treg.
Several groups, including ours, aimed at identifying markers
speciﬁc for Tr1 cells that distinguish them from other CD4+ T
cell subsets. Thus far, a number of candidate molecules have been
proposed, but unfortunately, most of them are not speciﬁc for
Tr1 cells. For example, a recent report indicated that the surface
expression of lymphocyte activation gene-3 (LAG-3) on CD4+
T cell correlates with IL-10 production and possibly Tr1 cells
(Okamura et al., 2009); however, LAG-3 has been shown to be
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Table 1 | Proposed markers of humanTr1 cells.
Molecule Tr1 cells Other cell types
Resting Activated Specific
LAG-3 Yes Yes ↑ No FOXP3+ Treg (Camisaschi et al., 2010)
ICOS Yes Yes ↑ No FOXP3+ Treg (Ito et al., 2008)
PD-1 Yes Yes ↑ No FOXP3+ Treg (Raimondi et al., 2006)
Tfh (Yu et al., 2009)
CD49b Yes Yes ? Th17 (Boisvert et al., 2010)
p-STAT3 Yes Yes ↑ No Th17 (de Beaucoudrey et al., 2008)
Tfh (Schmitt et al., 2009)
C-MAF Yes ? No Th2 (Rani et al., 2011)
Th17 (Hiramatsu et al., 2010)
AhR Yes ? No Th17 (Veldhoen et al., 2008)
Th22 (Trifari et al., 2009)
FOXP3 No Yes ↑ No FOXP3+ Treg (Hori et al., 2003)
↑, high level of expression; ?, indicates that data is not determined.
associated with FOXP3+ Treg (Camisaschi et al., 2010), making
LAG-3 an undependable marker for distinguishing Tr1 cells from
other Treg subsets. Similar to LAG-3, other proposed biomarkers
for Tr1 cells, such as inducible co-stimulatory molecule (ICOS;
Haringer et al., 2009), and programmed death receptor 1 (PD-1;
Akdis et al., 2004) have been associated with IL-10-producing T
cells, but, here again, they are also found on other T cell subsets.
Another report described the combined expression of the integrins
CD18high and CD49b as Tr1 cell-speciﬁc markers in peripheral
blood of healthy donors (Charbonnier et al., 2006; Rahmoun et al.,
2006). Unpublished results from our group also show that Tr1 cell
clones isolated fromnormal donors express higher levels of CD49b
compared to Th0 clones, whereas CD18 is expressed at similar lev-
els (Gagliani and Gregori, unpublished). In addition to surface
molecules, transcription factors known to regulate IL-10 expres-
sion such as STAT3 (Levings et al., 2001a), C-MAF (Pot et al.,
2009), and aryl hydrocarbon receptor (AhR; Apetoh et al., 2010)
have been used to identify human IL-10-producing T cells, but
it is still unclear if these transcription factors can be considered
master regulators and bona ﬁde markers for Tr1 cells (Table 1 for
summary of proposed markers). These data indicate that several
markers correlate with IL-10-producing T cells, but the search for
a unique and speciﬁc marker for human Tr1 cells has been as of
today not fruitful. Several studies, including gene expression pro-
ﬁling using ex vivo isolated Tr1 cell clones and in vitro generated
Tr1 cells, are ongoing to identify Tr1 speciﬁc markers.
Treg SUBSETS: DIFFERENT CELLS SHARING SIMILAR
MECHANISMS OF SUPPRESSION
MECHANISMS OF FOXP3+ Treg SUPPRESSION
Both naturally occurring and induced FOXP3+ Treg suppress
immune responses through several mechanisms, which can be
grouped into ﬁve basic modes of action: (i) cell-to-cell contact,
(ii)modulation of dendritic cells (DC), (iii) secretion of inhibitory
cytokines, (iv) metabolic disruption, and (v) cytolysis (review in
Vignali, 2008).
FOXP3+ Treg suppress effector T cell responses through still not
completely elucidated cell-to-cell contact dependent mechanisms
(Takahashi et al., 1998;Thornton andShevach,1998).Nonetheless,
it has been demonstrated that FOXP3+ Treg requires TCR activa-
tion (Thornton and Shevach, 2000) and IL-2 (Thornton et al.,
2004b) to exert their suppressive functions. The means by which
FOXP3+ Treg suppress is through the transcriptional inhibition of
IL-2 in effector T cells (Thornton and Shevach, 1998; Thornton
et al., 2004a) and IL-2 consumption (de la Rosa et al., 2004). The
molecular mechanisms underlying the suppression of IL-2 mRNA
in effector T cells is still unknown; however, it is independent of
TGF-β/IL-10 or IL-2 consumption (Oberle et al., 2007).
Modulation of DC function is another means by which
FOXP3+ Treg control T cell proliferation. FOXP3+ Treg regu-
late the catabolic enzyme indoleamine 2,3-dioxygenase (IDO) on
DC through the interaction of Cytotoxic T-Lymphocyte Antigen
4 (CTLA-4) with CD80/86 (Fallarino et al., 2003; Munn et al.,
2004). IDO inhibits effector T cell proliferation by reducing tryp-
tophan, which is necessary for cell division. In addition, FOXP3+
Treg can prevent DC activation by sending inhibitory signals to
the DC through the interaction of LAG-3 with the MHC class II
molecules (Liang et al., 2008).
FOXP3+ Treg secrete regulatory cytokines IL-10 (Ito et al.,
2008),TGF-β (Levings et al., 2001b; Stockis et al., 2009;Wang et al.,
2009),and IL-35 (Chaturvedi et al., 2011).While IL-10,TGF-β, and
IL-35 expression have been shown to be involved in suppression
mediated by human FOXP3+ Treg in vitro, it remains to be deﬁned
whether these cytokines contribute to their suppressive function
in vivo.
FOXP3+ Treg can also generate adenosine via the enzymatic
hydrolysis of extracellular ATP by the ectoenzymes CD39 and
CD73 (Deaglio et al., 2007), which disrupt the metabolic state
of effector T cells. Adenosine upon binding to its receptor,
the adenosine-speciﬁc A2A receptor (Borsellino et al., 2007),
suppresses inﬂammatory cytokine secretion by effector T cells in
a cyclic AMP (cAMP) dependent fashion (Bopp et al., 2007).
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Killing of target cells via the secretion of granzymes (Gzs) is
a well known feature of natural killer (NK) and cytotoxic CD8+
T cells (Cullen and Martin, 2008), but it is now evident that also
CD4+ T cells, including FOXP3+ Treg, can use Gzs to kill cells.
Upon activation FOXP3+ Treg express GzA and can lyse target cells
of both myeloid and lymphoid origin. Lysis mediated by FOXP3+
Treg requires CD18-mediated adhesion (Grossman et al., 2004a).
MECHANISMS OF Tr1-MEDIATED SUPPRESSION
Although multiple mechanisms of Tr1-mediated suppression have
been identiﬁed (Roncarolo et al., 2006), the relative importance of
each mechanism in vivo remains to be deﬁned since most of the
studies regarding human Tr1 cell activity have been done in vitro.
The main mechanism by which Tr1 cells mediate immune sup-
pression and promote tolerance is cytokine-mediated. However,
new evidences suggest that Tr1 cells are multifaceted suppressors
that use several modes of immune regulation to achieve toler-
ance. Tr1 cells indeed can inhibit T cell responses by cell contact
dependent mechanisms (Akdis et al., 2004), metabolic disruption
(Mandapathil et al., 2010), and cytolysis (Grossman et al., 2004b;
Magnani et al., 2011; see Table 2 for a summary of proposed Tr1
cells suppressive functions).
CYTOKINE-MEDIATED MECHANISMS OF SUPPRESSION BY Tr1 CELLS
The chief mechanismbywhichTr1 cells control immune responses
is through the secretion of high levels of the immunosuppres-
sive cytokines IL-10 and TGF-β (Bacchetta et al., 1994; Groux
et al., 1997; Barrat et al., 2002; Veldman et al., 2004). IL-10
Table 2 | Mode of suppression mediated byTr1 cells and/or
FOXP3+ Treg.
Tr1 cells FOXP3+ Treg
CYTOKINES
IL-10 Yes Still controversial (Ito et al.,
2008)
TGF-β Yes Yes (Levings et al., 2001b)
IL-35 Undeﬁned Yes (Chaturvedi et al., 2011)
CELL-TO-CELL CONTACT
CTLA-4 Yes Yes (Fallarino et al., 2003)
PD-1 Yes Undeﬁned
LAG-3 Undeﬁned Yes for murine cells (Liang
et al., 2008)
Undeﬁned for human cells
ICOS Undeﬁned Undeﬁned
LAP Undeﬁned Yes (Levings et al., 2001b;
Stockis et al., 2009; Wang
et al., 2009)
METABOLIC DISRUPTION
CD39 and CD73 Possible Yes (Borsellino et al., 2007)
cAMP Undeﬁned Yes for murine cells (Bopp
et al., 2007)
Undeﬁned for human cells
CYTOLYSIS
Granzyme A/perforin No Yes (Grossman et al., 2004b)
Granzyme-B/perforin Yes No (Grossman et al., 2004a)
directly suppresses T cell responses by inhibiting IL-2, IFN-γ,
and GM-CSF production by T cells (Vieira et al., 1991) and by
preventing proliferation (Taga and Tosato, 1992). Similarly, TGF-
β has potent immune-modulatory effects that directly inhibit T
cell responses (Gorelik and Flavell, 2002; Gorelik et al., 2002;
Figure 1A). Together, IL-10 and TGF-β secreted by Tr1 cell lines or
clones can inhibit IFN-γ production by T effector cells and limit
their proliferation (Cavani et al., 2000; Levings et al., 2005; Meiler
et al., 2008; Seraﬁni et al., 2009; Gregori et al., 2010). Whether IL-
10 andTGF-β expressed by Tr1 cellsmodulate other effector T cells
such as Th9 (Veldhoen et al., 2008), Th17 (Park et al., 2005), Th22
(Trifari et al., 2009), and T follicular helper (Tfh) cells (Crotty,
2011) has yet to be elucidated.
Type 1 regulatory T cells also suppress effector T cells indi-
rectly by inhibiting inﬂammatory factors and activating tolero-
genic pathways of antigen-presenting cells (APC; Roncarolo et al.,
2006).Manyof themolecules hinderedby IL-10onAPC, likeMHC
class II, co-stimulatory molecules (de Waal Malefyt et al., 1991),
and pro-inﬂammatory cytokines (Fiorentino et al., 1991a; Mosser
and Zhang, 2008) are important mediators of adaptive immune
responses. IL-10 treated APC, which up-regulate a number of
tolerogenic molecules, including immunoglobulin-like transcript
(ILT)-3 and 4 (Manavalan et al., 2003; Gregori et al., 2010), and
the non-classical HLA-G (Moreau et al., 1999;Gregori et al., 2010),
become regulatory cells capable of dampening immune responses
and inducing Treg (Morelli and Thomson, 2007; Gregori, 2011;
Figure 1A). For example, IL-10-treated macrophages or DC have
reduced abilities to secrete IL-12 after LPS activation and to induce
Th1 responses (Fiorentino et al., 1991b). It was demonstrated that
in allergic patients nickel-speciﬁc Tr1 cells inhibit DC to produce
IL-12 after LPS stimulation and nickel-speciﬁc Th1 cell responses
(Cavani et al., 2000).
B cells are targets of IL-10 and can promote tolerance by secret-
ing speciﬁc immunoglobulin subclasses (Scott-Taylor et al., 2010).
For example, activation of B cells in the presence of IL-10 prevents
apoptosis, enhances their proliferation, differentiation, and MHC
class II expression, and promotes immunoglobulin switching (Go
et al., 1990; Sabat, 2010). IL-10 derived from Tr1 cells promotes
IgG4 production by B cells (Satoguina et al., 2005), and in an
allergy setting, allergen-speciﬁc Tr1 cells induce IgG4 and suppress
IgE production via an IL-10-mediated mechanisms (Meiler et al.,
2008). Therefore, Tr1 cells promote tolerance also by modulating
B cell functions.
Interleukin-10 produced by Tr1 cells contributes to the gener-
ation of Treg. Our group showed that Ag stimulation of human
naïve CD4+ T cells in the presence of IL-10 promoted the induc-
tion of Tr1 cells in vitro (Bacchetta et al., 2002, 2010; Gregori
et al., 2010). Signaling through the IL-10 receptor (IL-10R) can
induce IL-10 production by CD4+ T cells (Barrat et al., 2002),
promote T cell anergy in CD4+ and CD8+ T cells (Groux et al.,
1996, 1998), and Tr1 cell differentiation (Groux et al., 1997) in
a STAT3-dependent manner. The importance of activating the
STAT3 pathway to induce Tr1 cells is highlighted by the fact that
other STAT3 activating cytokines such as IL-27 or IFN-α alone
(Awasthi et al., 2007; Fitzgerald et al., 2007; Murugaiyan et al.,
2009) or in combination with IL-10 (Levings et al., 2001a) pro-
mote Tr1 cells in vitro. Notably, a difference between the induction
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FIGURE 1 | Mechanisms of suppression mediated byTr1 cells. (A)Tr1
cells upon Ag-speciﬁc activation secrete IL-10 andTGF-β that directly
inhibit the function of effector T cells and indirectly modulate APC, which
in turn limit effector T cell proliferation and cytokine production. IL-10
produced byTr1 cells up-regulates the expression of tolerogenic
molecules (ILT3, ILT4, and HLA-G) on APC and their ability to produce
IL-10, and become regulatory APC able to promote de novo induction of
Tr1 cells. (B) CTLA-4 and PD-1 onTr1 cells down-regulate or prevent the
up-regulation of MHC class II and co-stimulatory molecules on APC upon
interaction with their ligand, which limits effector T cell activation. (C)
Catalytic inactivation of extracellular ATP by the ectoenzymes CD39 and
CD73 represents an anti-inﬂammatory mechanism used byTr1 cells to
prevent effector T cell proliferation and cytokine production. (D) IL-10
produced byTr1 cells upon activation promotes autocrine granzyme-B
(GZ-B) that in association with perforin (PRF) allows an Ag-non-speciﬁc
Tr1-mediated killing of myeloid APC. Myeloid-speciﬁc killing byTr1 cells
requires HLA class I activation and the expression of CD54, CD58,
CD112, and CD155 on myeloid cells.
of IL-10 in Tr1 cells and other IL-10-producing T cells is that IL-10
expression in non-Tr1 cells is STAT3 independent. For instance,
IL-10 production by Th1 cells requires strong TCR activation
and IL-12p70-induced STAT4 activation (Trinchieri, 2007; Saraiva
et al., 2009). Thus, IL-10 production by Tr1 cells is induced under
speciﬁc conditions compared to other IL-10-producing T cells and
STAT3activationmay represent a key signalingpathway that allows
these cells to maintain the expression of IL-10 at high levels.
The binding of IL-10 to its tetrameric, transmembrane IL-10R
composed of two IL-10R1 and two IL-10R2 molecules induces
the phosphorylation of Jak1 and Tyk2 within the intracellular
domain of IL-10R1, which acts as docking sites for STAT3 (Don-
nelly et al., 1999). After STAT3 docking and phosphorylation (p-),
p-STAT3homodimerizes in the cytoplasmand then translocates to
the nucleus, where it binds to STAT3-binding elements in the pro-
moters of various genes, including IL-10 (Donnelly et al., 1999),
and transcriptional repressors (i.e., SOCS3). STAT3 acts by selec-
tively inhibiting gene transcription of pro-inﬂammatory cytokines
such as TNF-α and IL-12p40 in APC (Murray, 2005). Moreover,
IL-10-induced SOCS3, which exerts negative regulatory effects on
various cytokine genes by inhibiting STAT and JAK2 activation, is
functioning in both T cells and APC (Mosser and Zhang, 2008).
In T cells, IL-10 also activates SOCS1, which negatively regulates
IFN-induced gene transcription (i.e., IP-10 and ISG-4; Asadullah
et al., 2003), whereas in APC, IL-10 selectively induces p50 nuclear
translocation while blocks the translocation of the classical NF-kB
heterodimer p65/p50 by inhibiting IKK activity (Wang et al., 1995;
Clarke et al., 1998). Together the molecular mechanism of IL-10
to dampen activation of both T cells and APC plays a major part
in regulating immune responses.
The broad immune-modulatory effects of IL-10 prompted
investigators to perform clinical trials using human recombi-
nant(r) IL-10 to treat inﬂammatory diseases. The earliest studies
performed in patients with psoriasis were encouraging; IL-10 was
tolerated well, and local subcutaneous administration of rIL-10
induced signiﬁcant clinical beneﬁts at the site of injection (Asadul-
lah et al., 1998). In a subsequent study in patients with more severe
forms of psoriasis the local delivery of rIL-10 to all lesions became
a major challenge, thus systemic administration of rIL-10 was
used but resulted in only temporary and local clinical improve-
ment (Asadullah et al., 2001). In addition, in patients with Chron’s
disease, and rheumatoid arthritis, subcutaneous administration
of rIL-10 was well tolerated but did not result in disease remis-
sion (Keystone et al., 1998; Schreiber et al., 2000). Unfortunately,
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patients from another Crohn’s disease trial using daily subcu-
taneous administration for 28 days of high doses of rIL-10 had
enhanced inﬂammatory T cell responses resulting in higher lev-
els of TNFα and IFNγ production (Tilg et al., 2002), suggesting
that high levels of systemic IL-10 can have a immune-stimulatory
effects. Taken together, these clinical trials indicate that IL-10 is
most effective when delivered locally to the site of inﬂamma-
tion. In this scenario the use of IL-10-producing Tr1 cells, which
produce high levels of IL-10 upon Ag-speciﬁc stimulation, repre-
sents an alternative approach to the delivery of IL-10 at the site of
Ag-speciﬁc inﬂammation.
Type 1 regulatory T cells indeed require TCR activation by
their cognate Ag to produce high amounts of IL-10 and to induce
bystander tolerogenic effects. Allergen-speciﬁc immunotherapy
(SIT) induces a signiﬁcant increase of Ag-speciﬁc IL-10-producing
Tr1 cells and elevated levels of IL-10 andTGF-β in peripheral blood
and allergic tissues in patients (Akkoc et al., 2011; Jutel and Akdis,
2011). The induction of Ag-speciﬁc Tr1 cells can lead to bystander
suppression in patients after SIT. Two independent groups demon-
strated that peptide-speciﬁc Tr1 cells induced after SIT could
down-regulate an established inﬂammatory response driven by
multiple T cell epitopes (Grindebacke et al., 2009; Yamanaka et al.,
2009). These bystander effects, however, do not lead to systemic
immuno-suppression, since tolerant patients with high frequency
of Tr1 cells and patients adoptively transferred with Tr1 cells
have normal immune responses to pathogens (Bacchetta et al.,
2009; Seraﬁni et al., 2009; Roncarolo et al., 2011; Bacchetta et al.,
submitted).
CELL CONTACT-DEPENDENT MECHANISMS OF SUPPRESSION BY Tr1
CELLS
Type 1 regulatory T cells express inhibitory receptors including
CTLA-4 (Bacchetta et al., 2002; Akdis et al., 2004), PD-1 (Akdis
et al., 2004), and ICOS (Haringer et al., 2009) that are known
to modulate T cell functions. CTLA-4 is a negative regulator of
T cell activation (Rudd et al., 2009) known to be expressed on
FOXP3+ Treg (Takahashi et al., 2000). Akdis et al. demonstrated
that allergen-speciﬁc Tr1 cells inhibit allergen-speciﬁc Th2 cells
via CTLA-4 (Akdis et al., 2004; Meiler et al., 2008) and suggested
that CTLA-4 co-operates with IL-10 and TGF-β in the suppres-
sion of allergic responses mediated by Tr1 cells. PD-1 is a receptor
that is critical for the regulation of T cell activation and function
during immunity and tolerance. PD-1 interactions with its lig-
ands PD-Ligand (L)1 and PD-L2 inhibit T cell effector functions
in an Ag-speciﬁc manner (reviewed in Fife and Pauken, 2011).
It has been shown that neutralization of PD-1 partially inhibits
Tr1-mediated suppression of allergen-speciﬁc T cells (Akdis et al.,
2004; Meiler et al., 2008), suggesting that PD-1 plays a role in
the suppression mediated by Tr1 cells (Figure 1B). Despite these
results it remains to be deﬁned to what extent Tr1 cells exploit
cell-to-cell contact mechanisms to control immune responses.
ROLE OF METABOLIC DISRUPTION IN Tr1 CELL-MEDIATED
SUPPRESSION
Like FOXP3+ Treg,Tr1 cells can express the ectoenzymesCD39 and
CD73 (Bergmann et al., 2007; Mandapathil et al., 2010) and are
believed to use these enzymes to generate the immunosuppressive
molecule adenosine. Bergmann et al. (2007) showed that in vitro
generated IL-10-producing T cells in the presence of cyclooxyge-
nase 2 (COX2)-expressing cells and immature DC express CD39
and CD73. Furthermore, Mandapathil et al. (2010) showed that
adenosine generated by Tr1 cells suppresses proliferation and
cytokine productionof effectorT cells uponbindingwith its recep-
tor (Figure 1C). We have found that human Tr1 cell clones also
express signiﬁcantly higher levels of mRNA encoding for CD39
compared to Th0 cell clones (Gregori et al., unpublished data).
These results suggest that metabolic disruption of conventional T
cells might represent an additional mechanism used by Tr1 cells
to mediate suppression.
CYTOLYTIC ACTIVITY OF Tr1 CELLS
HumanTr1 cells, depending on themode of activation/generation,
can express both GzA and GzB and selectively kill target cells
(Grossman et al., 2004b; Kawamura et al., 2006; Eﬁmova and Kel-
ley,2009;Czystowska et al.,2011;Magnani et al., 2011).We recently
demonstrated that human Tr1 cells, generated in vitro and isolated
ex vivo, express and release high levels of GzB, and speciﬁcally lyse
cells of myeloid origin, but not other APC or T and B lympho-
cytes (Magnani et al., 2011). Tr1-mediated cytotoxicity of myeloid
APC is Ag-independent and requires recognition and activation
via HLA class I molecules expressed on target cells (Figure 1D).
This differs from NK cells, which kill target cells lacking HLA class
I molecules. Speciﬁc killing of myeloid APC by Tr1 cells depends
on the high expression levels of CD54, CD58, CD155, and CD112
on myeloid cells, which, upon interaction with their ligands on Tr1
cells, mediate stable Tr1/APC adhesion and Tr1 speciﬁc activation
(Magnani et al., 2011). Killing of myeloid cells by Tr1 cells repre-
sents an additional indirect mechanism of suppression,which may
contribute to bystander suppression. It is tempting to speculate
that upon encounter with their cognate Ag Tr1 cells up-regulate
GzB expression and kill myeloid cells in an Ag-non-speciﬁc man-
ner. This indirect effect could result in a reduction of allo-reactive
APC in the case of transplantation, or APC that present self-Ags in
the case of autoimmune diseases, limiting priming and expansion
of effector T cells.
COMPARISON BETWEEN THE SUPPRESSIVE ACTIVITIES OF
FOXP3+ Treg AND Tr1 CELLS
FOXP3+ Treg and Tr1 cells have distinct and shared mechanisms
of suppression (see Table 2). The main distinction is that Tr1 cells
suppress immune responses primarily via IL-10,whereas FOXP3+
Treg regulate effector T cells principally via T:T cell contact medi-
ated mechanisms. TGF-β is used by both cell subsets to modulate
T cell responses, but Tr1 cells secrete TGF-β upon activation via
their TCR, while FOXP3+ Treg express TGF-β on the cell surface
in a complex with latent associated peptide (LAP; Nakamura et al.,
2001). More recently, it has been shown that GARP, an orphan
toll-like receptor, is selectively expressed by activated FOXP3+ Treg
and is required for LAP expression (Stockis et al., 2009; Tran et al.,
2009). GARP by interacting with LAP in activated FOXP3+ Treg
delivers LAP to their cell surface allowing suppression (Battaglia
and Roncarolo, 2009; Stockis et al., 2009). It remains to be deﬁned
whether human Tr1 cells express LAP and GARP upon activation,
and if they use LAP to suppress T cell responses.
Frontiers in Immunology | T Cell Biology February 2012 | Volume 3 | Article 30 | 6
Gregori et al. Immuno-regulatory mechanisms of Tr1 cells
Induction of tolerogenic APC by FOXP3+ Treg and Tr1 cells is
a common mechanism of suppression. Since both T cell subsets
express CTLA-4 it is likely that they induce similar tolerogenic
signals in APC; however, it is still elusive whether the interac-
tion between Tr1 cells and APC will lead to IDO expression as it
has been demonstrated for FOXP3+ Treg (Fallarino et al., 2003).
Moreover, additional studies are needed to deﬁne if the interac-
tion between CTLA-4 on Tr1 cells and CD86 on APC synergizes
with IL-10 to inhibit up-regulation of co-stimulatory molecules
on APC.
Metabolic disruption of effector T cells by FOXP3+ Treg and
Tr1 cells represents an additional common mechanism of immune
suppression. Both FOXP3+ Treg and Tr1 cells express CD39 and
CD73 and produce adenosine. On the contrary cytolysis mediated
by FOXP3+ Treg and Tr1 cells is distinct: FOXP3+ Treg lyse a wide
array of immune cells (Grossman et al., 2004b), whereas Tr1 cells
speciﬁcally kill myeloid cells (Magnani et al., 2011).
PRE-CLINICAL MODELS TO TEST SAFETY AND EFFICACY OF
HUMAN Treg-BASED THERAPY
Adoptive transfer of Treg to restore or induce tolerance toward
self-Ags or allo-Ags is an efﬁcient means to prevent or cure
several T cell mediated diseases, including GvHD, allograft rejec-
tion, autoimmunity, and chronic inﬂammatory diseases in pre-
clinical mouse models (Bluestone et al., 2007; Roncarolo and
Battaglia, 2007). To evaluate the efﬁcacy of human FOXP3+ Treg
therapy in vivo humanized mouse models of xeno-GvHD and
of allogeneic T cell responses have been developed. Kleinewi-
etfeld et al. (2009) showed that adoptive transfer of human
CD4+CD27−CD49d−FOXP3+ Treg is an effective means to pre-
vent xeno-GvHD induced by human PBMC in Rag2−/−γc−/−
mice. Similarly, injection of in vitro expanded human FOXP3+
Treg with artiﬁcialAPC expressingCD86 andCD64 in the presence
of anti-CD3 mAbs, IL-2 and rapamycin could block xeno-GvHD
induced by humanPBMC inNOD/scid IL2Rγcnull mice (Golovina
et al., 2008),while only partially delayed xeno-GvHD in NOD/scid
mice (Hippen et al., 2011). In addition, preliminary results by
our research group showed that human T cells engineered to
stably over-express FOXP3 suppress xeno-GvHD in humanized
NOD/scid mice (Passerini and Bacchetta, unpublished).
The efﬁcacy of Treg-based cell therapy with human FOXP3+
Treg to suppress allogeneicT cell responses in vivo has been recently
evaluated. In this study Sagoo et al. (2011) demonstrated in a
humanized mouse allo-skin graft model that adoptive transfer
of expanded alloAg-speciﬁc human CD4+CD25highCD127low/−
Treg, but not expanded polyclonal CD4+CD25highCD127low/−
Treg, signiﬁcantly improved protection of human skin damage.
In addition, the group of K. Wood demonstrated that transfer
of in vitro expanded polyclonal CD4+CD25highCD127low/− Treg
(Nadig et al., 2010) or in vitro induced FOXP3+ Treg (Feng et al.,
2011) prevented ateroesclerosis in a humanized model. Taken
together, adoptive transfer of human FOXP3+ Treg is a promising
means to control T cell-mediated diseases in humanized mouse
models suggesting that the efﬁcacy of human Treg-based ther-
apy may mirror the data garnered from the numerous pre-clinical
mouse studies.
The effectiveness of Tr1-based cell therapy to control xeno-
GvHD is under investigation by our group. We have recently
demonstrated in a humanized mouse model that human IL-10-
producing CD4+ Tr1 cells, generated by transducing CD4+ T
cells with a lentiviral vector encoding for IL-10, suppress xeno-
GvHD and promote survival when co-transferred with allogeneic
PBMC (Andolﬁ and Fousteri, submitted). Additional studies are
needed to deﬁne which are the mechanisms of in vivo suppression
mediated by FOXP3 Treg and Tr1 cells.
CLINICAL TRIAL WITH Treg CELLS
Results obtained in pre-clinical studies and the evidence that Treg
are critically involved in promoting peripheral tolerance prompted
investigators to use adoptive transfer of Treg as a therapeutic.
Proof-of-principle clinical trials in allogeneicHSCTdemonstrated
the safety of Treg-based cell therapy with both FOXP3+ Treg,
ex vivo isolated (Trzonkowski et al., 2009; Di Ianni et al., 2011;
Edinger and Hoffmann, 2011) or in vitro expanded (Brunstein
et al., 2010), and Tr1 cells (Bacchetta et al., 2009; Bacchetta, sub-
mitted). Furthermore, a phase I/II trial showed that cell therapy
with Tr1 cell clones in patients displaying severe Crohn’s disease is
safe and does not lead to general immuno-suppression1. One of
1http://www.txcell.com
Table 3 | Clinical trials withTreg-based cell therapy.
Trial Disease Methods of generation Ag-specificity
In vitro induction In vitro expansion Ex vivo isolation
TR1 CELLS
Allo-speciﬁc (Bacchetta et al., 2009) Allo-HSCT Yes No No Yes
OVA-speciﬁc (http://www.txcell.com) Crohn’s disease No Yes No Yes
TREG CELLS
CD25high cells (Di Ianni et al., 2011) Allo-HSCT No No Yes No
CD25high cells (Brunstein et al., 2010) Allo-HSCT No Yes Yes No
CD25high cells (Trzonkowski et al., 2009) Allo-HSCT No Yes Yes No
CD25high cells (Edinger and Hoffmann, 2011) Allo-HSCT No No Yes No
CD25+CD127low/− cells (ClinicalTrials.gov
Identiﬁer: NCT01210664)
T1D No Yes Yes No
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the advantages of using Tr1 cells over FOXP3+ Treg, is that Tr1 cells
are inducible ex vivo and, therefore, canbe generated and expanded
in vitro against the required Ag-speciﬁcity. Taken together, results
from these clinical trials suggest that: (i) FOXP3+ Treg may pre-
vent GvHD without inhibiting prompt immune reconstitution in
allo-HSCT (Brunstein et al., 2010; Di Ianni et al., 2011; Edinger
and Hoffmann, 2011), (ii) allo-speciﬁc Tr1 cells promote faster
immune reconstitution (Bacchetta et al., 2009; Bacchetta, sub-
mitted), (iii) infusion of autologous Ag-speciﬁc Tr1 cell clones in
patients with Chron’s disease has beneﬁcial effects (see text foot-
note 1). Several open questions regarding Treg-based therapy in
humans remain: how long do Treg survive in vivo after transfer,
what is their mechanism of suppression in vivo, and whether Ag-
speciﬁcity is required to induce long-term tolerance (see Table 3).
Caution for Tr1-based cell therapy should be used considering
the adverse effects of excessive levels of systemic IL-10 demon-
strated in rIL-10 clinical trials (Tilg et al., 2002; Mosser and Zhang,
2008).
Future clinical trials planning to test the safety and efﬁcacy
of Treg-based therapy in patients after allogeneic organ trans-
plant (THE ONE study)2 as well as in patients with autoim-
mune diseases, such as type 1 diabetes (ClinicalTrials.gov Iden-
tiﬁer: NCT01210664) and rheumatoid arthritis (see text footnote
1) will deﬁne if Treg can suppress allograft rejection under the
umbrella of immune suppression, and whether Treg can suppress
self-Ag speciﬁc T cell responses, and can regulate an ongoing
2http://www.onestudy.org/
immune response. Overall, these studies will deﬁne the efﬁcacy
of Treg-based therapy as therapeutic option to restore or induce
tolerance in T cell mediated diseases.
CONCLUSION
Since the discovery of Tr1 cells nearly two decades ago, research
has ﬁrmly established their role in controlling immune home-
ostasis and modulating a wide variety of diseases. While a great
deal of progress has been made in understanding the mechanisms
of suppression by Tr1 cells, a number of questions still remain.
First, a unique set of surface or intracellular marker(s) for Tr1 cells
remains to be identiﬁed. Second, although it is well established
that FOXP3+ Treg and Tr1 cells are distinct populations sharing
similar mechanism of suppression, additional research is needed
to deﬁnewhat the relationship is between these Treg subsets. Third,
since there are severalmechanisms of suppressionused byTr1 cells,
it needs to be determined whether these mechanisms are opera-
tional in vivo and whether they are speciﬁc to a particular disease
state. Answering these questions will not only bring us closer to
understanding how Tr1 cells function, but also how to exploit or
modulate their suppressive activity for targeted therapy against a
wide variety of diseases.
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